Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

To irradiate or not to irradiate—that is the question

Nature Clinical Practice Oncology volume 2, pages 76–77 (2005)Cite this article

boxed-textHorning SJ et al. (2004) Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group Study 1484. J Clin Oncol 22: 3032–3038

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Vaughan-Hudson B et al. (1994) Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 69: 1088–1093

    Article  CAS  Google Scholar 

  2. Fisher RI et al. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328: 1002–1006

    Article  CAS  Google Scholar 

  3. Miller TP et al. (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339: 21–26

    Article  CAS  Google Scholar 

  4. Reyes F et al. (2000) Superiority of the ACVBP regimen over a combined treatment with three cycles of CHOP followed by involved field radiotherapy in patients with low risk localized aggressive non-Hodgkin's lymphoma: Results of the LNH93-1 study [abstract]. Blood 96: 532a

    Google Scholar 

  5. Pfreundschuh M et al. (2004) First analysis of the completed Mabthera International (MInT) Trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL): addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI=O and no bulky disease [abstract]. Blood 104: 48a

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor and Chairman of the Department of Haematology and Oncology, Georg August University, Göttingen, Germany

    Lorenz H Trümper

Authors
  1. Lorenz H Trümper
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

No employment of personal financial interests. Research funding was provided for clinical trials by Roche and AMGEN. Principal Investigator of the MINT trial, sponsored by Roche.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trümper, L. To irradiate or not to irradiate—that is the question. Nat Rev Clin Oncol 2, 76–77 (2005). https://doi.org/10.1038/ncponc0082

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0082

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing